Backman named associate director for research technology at Northwestern

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Vadim Backman was named associate director for Research Technology and Infrastructure at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University.

In addition to this new role, Backman, the Walter Dill Scott Professor of Biomedical Engineering at the McCormick School of Engineering and Applied Sciences, will continue to serve as leader of the Cancer and Physical Sciences Program at the Lurie Cancer Center.

As associate director, Backman will oversee Lurie Cancer Center’s infrastructure for interdisciplinary programs and initiatives, which include the center’s 16 Shared Resources that foster basic, clinical and translational research. He will also lead the development of innovative tools, technologies and services to support emerging disciplines across the cancer center.

Backman succeeds Milan Mrksich, the Henry Wade Rogers Professor, who was recently named Northwestern University’s interim vice president for research.

An expert in biomedical optics, Backman has developed numerous imaging technologies. Through his nanocytology technique, he developed a simple, easy-to-use test for diagnosing multiple forms of cancer at the earliest stage of disease formation. He leads Northwestern’s new Center for Physical Genomics and Engineering, focused on the entirely new field using optical imaging and computational genomics to reprogram the genome’s chromatin, which regulates gene expression.

Table of Contents

YOU MAY BE INTERESTED IN

For nearly 25 years, business executive Lou Weisbach and urologist Richard J. Boxer have argued that finding the money to finance the cures for devastating diseases is not as difficult as it appears. To start finding the cures, the U.S. Department of the Treasury needs to issue some bonds—$750 billion worth. Next, you hire CEOs—one...

There is general agreement that the United States spends too much on health care, especially on pharmaceuticals.  But what we spend on drugs is not simply a function of price. If eggs double in price, people can simply cut the number of eggs they eat in half.  Simply stated, cost is the product of (price per unit times the number of units purchased). 
What did President Richard M. Nixon and Senator Edward M. Kennedy have in common? They each played a pivotal role in the passage of the National Cancer Act signed by Nixon on Dec. 23, 1971. The NCA established the National Cancer Program authorizing the initial investment in the NCI-designated Cancer Centers Program. 
When I first proposed targeting PCNA (proliferating cell nuclear antigen) as a therapeutic approach, the response I got was: “No one will ever make a drug against PCNA. It’s undruggable.” The protein lacks enzymatic activity, has a disordered region, and binds to over 200 other proteins within the cell. From a traditional drug development perspective, these characteristics made PCNA an impossible target.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login